<DOC>
	<DOCNO>NCT00581113</DOCNO>
	<brief_summary>For patient 1-6 intraparenchymal brain metastasis various primary histology ( except melanoma ) , stereotactic radiosurgery ( administer upfront concurrently ) complete surgical resection neural stem cell ( NSC ) -preserving whole-brain radiotherapy ( WBRT ) result improve neurocognitive profile standard WBRT . The goal study assess feasibility treatment approach .</brief_summary>
	<brief_title>Neural Stem Cell Preserving Brain Radiation Therapy &amp; Stereotactic Radiosurgery Patients With 1-6 Brain Metastases</brief_title>
	<detailed_description>Cancer patient ( except patient melanoma ) 1-6 brain metastasis randomize receive standard whole brain radiation therapy whole brain radiation therapy neural stem cell-preserving manner .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Histologically confirm nonmelanoma primary malignancy 16 intraparenchymal brain metastasis ( small cell lung cancer consider prophylactic brain irradiation ( PBI ) demonstrable intracranial lesion ) . A diagnostic contrastenhanced magnetic resonance imaging ( MRI ) demonstrate presence 16 brain metastasis perform within 4 week registration . Note : If small cell lung cancer primary patient consider PBI , MRI must demonstrate intracranial lesion . Patients totally resect intraparenchymal brain metastasis ; lesion need resect criterion satisfy ( 6 total lesion ) The contrastenhancing intraparenchymal brain tumor must well circumscribe must maximum diameter 4 cm dimension enhance scan . If multiple lesion present one lesion maximum diameter , ( ) must exceed 3.0 cm maximum diameter . Metastatic lesion must distribute peripherally , , least 0.5 cm lateral ( outside ) lateral ventricle and/or hippocampus bilaterally . Posterior fossa metastatic lesion allow study . Age 18 year old . Zubrod performance score 01 . Neurologic function score 0 , 1 , 2 . Patients receive glucocorticoid taper low possible dose , altogether , judge participate physician . If glucocorticoid dose adjust give first time , patient must remain stable dose glucocorticoid least 3 day prior initial Neurocognitive Assessment Protocol ( NAP ) , CT MR image . Major medical illness psychiatric impairment , investigator opinion prevent administration completion protocol therapy and/or interfere followup . For patient undergone subtotal resection , residual disease must 4 cm maximum diameter . Inability obtain histologic proof primary malignancy . Patients leptomeningial metastasis document MRI cerebral spinal fluid ( CSF ) evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>whole brain radiotherapy</keyword>
	<keyword>neural stem cell</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>radiosurgery</keyword>
</DOC>